维多珠单抗、阿达木单抗与英夫利西单抗对原发性硬化性胆管炎合并炎症性肠病患者胆道炎症的影响
该回顾性队列研究纳入88例合并原发性硬化性胆管炎的炎症性肠病患者,比较维多珠单抗、阿达木单抗与英夫利西单抗治疗前后肝功能指标变化。阿达木单抗组在6-8个月时碱性磷酸酶较维多珠单抗组和英夫利西单抗组显著下降,但12-14个月时差异不显著,其他指标均无显著下降。作者认为现有证据提示生物制剂对原发性硬化性胆管炎无效,阿达木单抗的潜在获益需进一步研究。
要点
- 阿达木单抗组6-8个月碱性磷酸酶较维多珠单抗组和英夫利西单抗组显著下降,但12-14个月差异不显著。
- 任何生物制剂治疗后6-8个月或12-14个月,AST、ALT、总胆红素、直接胆红素、弹性成像评分或胆道扩张/狭窄影像均无显著下降。
- 作者认为现有证据提示用于炎症性肠病的生物制剂并非原发性硬化性胆管炎的有效治疗。
核心结论
- 作者认为现有证据提示用于治疗炎症性肠病的生物制剂并非原发性硬化性胆管炎的有效治疗,阿达木单抗对原发性硬化性胆管炎的潜在获益需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入88例合并原发性硬化性胆管炎的炎症性肠病病例(75例唯一患者,其中12例接受过1种以上生物制剂),包括48例溃疡性结肠炎、24例克罗恩病和3例未定型结肠炎。
- 患者于2002年6月至2017年10月期间接受生物制剂治疗:英夫利西单抗42例、阿达木单抗19例、维多珠单抗27例。
- 采用配对t检验比较生物制剂启动前≤3个月与启动后6-8个月及12-14个月的肝脏生化指标,患者自身作为对照;通过腹部超声、腹部磁共振成像和磁共振弹性成像获取胆道狭窄和肝纤维化的影像学信息。
主要发现
- 阿达木单抗组6-8个月碱性磷酸酶较维多珠单抗组和英夫利西单抗组显著下降(P=0.03;阿达木单抗组平均变化-70 U/L,标准差88 U/L;维多珠单抗组平均变化+50 U/L,标准差142 U/L;英夫利西单抗组平均变化+37 U/L,标准差183 U/L)。
- 12-14个月时上述碱性磷酸酶变化不显著(P=0.24)。
- 任何生物制剂治疗后6-8个月或12-14个月,AST、ALT、总胆红素、直接胆红素、弹性成像评分或胆道扩张/狭窄影像均无显著下降。
临床怎么用
- 作者认为现有证据提示用于治疗炎症性肠病的生物制剂并非原发性硬化性胆管炎的有效治疗,阿达木单抗对原发性硬化性胆管炎的潜在获益需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure. AIM: To evaluate the effect of biological therapies on PSC progression in IBD patients. METHODS: We performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were compared using the paired t-test (patients served as their own controls) ≤3 months before and 6-8 and 12-14 months after biological initiation. Radiographic information of biliary stenosis and liver fibrosis were obtained via abdominal ultrasound, abdominal magnetic resonance imaging and magnetic resonance elastography. RESULTS: Use of adalimumab was associated with a significant decrease in alkaline phosphatase (ALP) after 6-8 months (P = 0.03; mean change -70 U/L, standard deviation [SD] 88 U/L) compared to vedolizumab (mean change +50 U/L, SD 142 U/L) or infliximab (mean change +37 U/L, SD 183 U/L) but the change was not significant after 12-14 months (P = 0.24). No significant decreases were observed with AST, ALT, total or direct bilirubin, elastography score or radiographic imaging of biliary tree dilation/strictures with any biological therapy after 6-8 or 12-14 months. CONCLUSIONS: Current evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.
引用
- Tse CS, Loftus EV, Raffals LE, et al. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29808485. doi:10.1111/apt.14829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。